Cubist is going through a bad patch with outsourced production. The problems began in August 2013, when CMO quality failings prompted Cubist to recall four lots of its injectable antibiotic Cubicin. Having summoned back another lot in April, Cubist has now issued a much larger recall, with about 100 lots affected.
Contract services company Aptuit will invest $1 million in its facility in Glasgow, Scotland, to expand its capacity to manufacture sterile cytotoxic liquid and lyophilized drug products.
While geopolitical instability in Eastern Europe would appear to make Russia a risky bet, the size of the market and incoming targets on drug production mean the likes of Abbott Laboratories are still investing. For companies unwilling or unable to strike deals like Abbott's $495 million buyout of Veropharm, a new option is tipped to emerge: CMOs.
California contract manufacturer Laclede was warned. Now it is being legally stormed. After years of letters, inspections and meetings with the FDA couldn't move the company to seek an NDA for its vaginal gel products, the FDA has sued Laclede to get it to stop making them.
A new company, initially dubbed NewCo and created by the $2.6 billion merger of contract manufacturer Patheon and Netherlands-based DSM Pharmaceutical Products, has officially broken onto the scene. It has been given the moniker of DPx and starts its corporate life as one of the largest contract manufacturing and development groups in the world.
A voluntary recall was issued Friday after there was a report of a single visible glass particle in a vial in a lot that was produced for Genco Pharmaceutical Services.
With the the coming entry of biosimilars in the U.S. and expansion of that market in Europe, biologic drugs are going to be in greater demand, as will the contract manufacturers who can supply the cell lines and special services needed to get them to market. Okalahoma-based Cytovance Biologics is joining a number of CMOs that are adding capacities to tap that growth.
Aesica, the U.K.-based contract manufacturer, has a new plant going online but one with a very specialized purpose.
The way execs at Piramal Healthcare see it, there are good reasons to expand production at Piramal's hormonal medicines plant in Morpeth, U.K. The market is worth $11 billion and growing at 4% to 5% a year, and there are not many contract manufacturers that play in that space. And so the Indian manufacturer will triple production there.
International Chemical Investors Group (ICIG) has nabbed another operation to fold into its contract manufacturing arm Corden Pharma group: Peptisyntha, a Brussels, Belgium-based custom manufacturer of peptides for pharmaceuticals. It will become its third site offering this service.